With evidence-based clinical development and new pharmaceutical formulations, Avextra aims to increase patient experience and adherence
Bensheim, Germany, December 3rd 2025 — How can therapy with Cannabis-based medicines (CbM) be designed to be not only therapeutically proven, but also patient-friendly and safe? To date, oily solutions have dominated the medical market in the area of statutory health insurance especially for pain patients. Despite already existing robust evidence of the effectiveness of oily cannabis extracts, new standardized oral dosage forms of CbM are becoming more and more important to overcome gaps in simplify handling and thus to increase patient adherence. Avextra, the German biotech company, is now launching a new portfolio that combines standardized quality and innovative dosage forms such as capsules.